Spero Therapeutics (NASDAQ:SPRO) Given New $5.00 Price Target at HC Wainwright

Spero Therapeutics (NASDAQ:SPRO) had its target price cut by HC Wainwright from $7.00 to $5.00 in a report published on Monday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Spero Therapeutics’ Q3 2024 earnings at $0.02 EPS, Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.75) EPS, Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at $0.10 EPS and FY2025 earnings at ($0.33) EPS.

Other research analysts also recently issued research reports about the stock. TD Cowen upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research report on Tuesday, August 6th.

Spero Therapeutics Stock Performance

NASDAQ:SPRO opened at $1.31 on Monday. The stock has a market capitalization of $70.73 million, a P/E ratio of 3.97 and a beta of 0.63. Spero Therapeutics has a 1 year low of $1.01 and a 1 year high of $1.89. The firm has a 50 day moving average of $1.30 and a 200-day moving average of $1.37.

Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.01. The firm had revenue of $10.20 million during the quarter, compared to the consensus estimate of $9.80 million. Spero Therapeutics had a return on equity of 25.67% and a net margin of 14.74%. During the same quarter in the previous year, the company posted ($0.23) EPS. As a group, analysts forecast that Spero Therapeutics will post -1.59 EPS for the current fiscal year.

Hedge Funds Weigh In On Spero Therapeutics

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Spero Therapeutics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after purchasing an additional 9,675 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of Spero Therapeutics by 121.8% during the first quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock worth $1,310,000 after buying an additional 418,742 shares during the last quarter. Murchinson Ltd. lifted its holdings in Spero Therapeutics by 1.3% in the first quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock valued at $1,503,000 after buying an additional 11,210 shares during the period. Virtu Financial LLC bought a new position in Spero Therapeutics in the first quarter valued at approximately $31,000. Finally, Renaissance Technologies LLC grew its holdings in Spero Therapeutics by 14.2% during the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock worth $1,269,000 after acquiring an additional 121,492 shares during the period. Institutional investors and hedge funds own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.